Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution

Melanoma Research

Volumn 8, Issue 4, 1998, Pages 337-343

  Hofbauer, G F L ^a   Kamarashev, J ^a   Geertsen, R ^a   Boni R ^a   Dummer, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Immunohistochemistry; Melan A MART 1; Melanoma; Monoclonal antibody

Indexed keywords

ALKALINE PHOSPHATASE; DIFFERENTIATION ANTIGEN; EPITOPE; MELAN A; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIXATIVES; FORMALDEHYDE; HUMANS; IMMUNOENZYME TECHNIQUES; MELANOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; NEVUS, PIGMENTED; PARAFFIN EMBEDDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SKIN NEOPLASMS; TISSUE FIXATION; TUMOR CELLS, CULTURED;

EID: 0031659143     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199808000-00007     Document Type: Article

References (27)

1. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177: 989-998.
2. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
3. Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumour rejection antigens. Immunol Res 1996; 15: 179-190.
4. Marincola FM, Rivoltini L, Salgaller ML, Player T, Rosenberg SA. Differential anti-mart-1/melanA CTL activity in peripheral blood of HLA-a2 melanoma patients in comparison to healthy donors evidence of in vivo priming by tumour cells. J Immunother 1996; 19: 266-277.
5. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, et al. Induction of tumour-reactive CTL from peripheral blood and tumour-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154: 2257-2265.
6. Kawakami Y, Battles JK, Kobayashi T, Ennis W, Wang X, Tupesis JP, Marincola FM, Robbins PF, Hearing VJ, Gonda MA, Rosenberg SA. Production of recombinant mart-1 proteins and specific antimart-1 polyclonal and monoclonal antibodies - use in the characterization of the human melanoma antigen mart-1. J Immunol Methods 1997; 202: 13-25.
7. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, Old LJ. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93: 5915-5919.
8. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-229.
9. Hofbauer G, Schaefer C, Noppen C, Böni R, Kamarashev J, Spagnioli G, Dummer R. MAGE-3 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151: 1549-1553.
10. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 1996; 88: 1383-1389.
11. Boon T, Vanderbruggen P. Human tumour antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
12. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996; 6: 11-24.
13. Dummer R, Davis-Daneshfar A, Dohring C, Dobbeling U, Burg G. Strategien zur Gentherapie des Melanoms. Hautarzt 1995; 46: 305-308.
14. Bueler H, Mulligan RC. Induction of antigen-specific tumour immunity by genetic and cellular vaccines against Mage - enhanced tumour protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med 1996; 2: 545-555.
15. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al. Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 883-885(letter).
16. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-2483.
17. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the melanoma-associated antigens Mart-1 and Gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996; 19: 192-205.
18. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D, Oesch F, Knuth A. Immunoselection in vivo - independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71: 142-147.
19. Albino AP, Fountain JW. Molecular genetics of human malignant melanoma. Cancer Treat Res 1993; 65: 201-255.
20. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumour-rejection antigens. Annu Rev Med 1996; 47: 481-491.
21. Gattoni-Celli S, Cole DJ. Melanoma-associated tumour antigens and their clinical relevance to immunotherapy. Semin Oncol 1996; 23: 754-758.
22. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 1997; 7: 83-95.
23. Gudat F, Zuber M, Durmuller U, Kocher T, Schaefer C, Noppen C, Spagnoli G. The tumour-associated antigen Mage-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchow Arch 1996; 429: 77-81.
24. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumours distinguish subpopulations of melanocytes. Am J Pathol 1986; 123: 195-203.
25. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92: 8125-8129.
26. Sato N, Suzuki S, Takimoto H, Masui S, Shibata K, Nakano H, Tomita Y. Monoclonal antibody Mat-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections. Pigment Cell Res 1996; 9: 72-76.
27. Hofbauer GFL, Kamarashev J, Geertsen R, Böni R, Dummer R. Tyrosinase immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 1998; 25: 204-209.